According to data compiled by Bloomberg, around 16.6 million shares of Biocon changed hands on the BSE in a single pre-market ...

In Biocon’s continuing effort to divest and Eris Lifesciences’ attempt to grow, the companies have expanded a previous agreement, with Bangalore-based generics giant Biocon selling Indian branded ...

True North is expected to be the seller in the transaction. The investment firm holds its Biocon stake through Activ Pine LLP ...

ICICI Prudential Mutual Fund emerged as the largest buyer, acquiring additional 74.03 lakh shares for Rs 285.02 crore. It was ...

Biocon shares rose after a block deal involving around 1.65 crore shares. Investor Active Pine was reportedly looking to sell ...

Active Pine is likely to sell up to 1.66 crore Biocon shares, equivalent to 1% equity, through a block deal worth ₹638.4 ...

Biocon's Q1 net profit declined 95% year-on-year, but on a like-for-like basis, profit after tax increased by 65%. Revenue ...

Viatris Inc. , the company formed by the merger of Mylan and Pfizer Inc. unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with Biocon Biologics Ltd.

Pertuzumab is an antibody used to treat HER2-positive breast cancer and is currently not manufactured locally in Brazil.

Viatris is leaving the biosimilar field just months after winning the landmark FDA approval for the first interchangeable biosimilar product. Biocon Biologics, a subsidiary of Biocon, will buy Viatris ...

Biocon stock price today: Shares of Kiran Mazumdar Shaw-led Biocon extended gains to settle five per cent higher on Tuesday, December 24, after the United States Food and Drug Administration (USFDA) ...

Biocon Biologics has been positioning itself to become a global player in biosimilar drugs. Viatris, a longtime partner to Biocon, is charting a course for its future that does not include biosimilars ...